Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01371968

Enrollment

Registered

2011-06-13

Start date

2011-02-28

Completion date

2011-11-30

Last updated

2017-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Response

Keywords

Alfentanil, optimal dose, laryngeal mask airway

Brief summary

This study aims to determine the optimal dose of alfentanil in suppressing the airway reflexes during supreme LMA removal in anaesthetized adult.

Detailed description

The removal of LMA may be associated with coughing, biting, agitation and airway complication such as laryngospasm. Thus it is advisable to remove the LMA when the patient is breathing spontaneously and when the airway reflexes are still depressed. A number of techniques have been used to prevent this adverse emergence phenomenon, such as removing the tube while the patient is in deep plane of anaesthesia or administration of local anaesthetic and intravenous opioids The administration of intravenous opioids before emergence may be useful for preventing cough, agitation and hemodynamic response. Alfentanyl is proven to suppress cough and agitation during the endotracheal tube emergence. However, its use in suppressing cough in LMA patient has not been evaluated.

Interventions

DRUGalfentanil

Alfentanil is administered intravenously at the end of surgery.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 49 Years

Healthy volunteers

Yes

Inclusion criteria

1. ASA I and II patients 2. Age 18 to 49 years old 3. Minor elective day care surgery (\> 20 minute and less than 2 hours) which require local anaesthetic infiltration and does not require use of long acting opioids.

Exclusion criteria

1. Potential difficult airway 2. Reactive airway disease or sign and symptoms of upper respiratory tract infection. 3. History of cardiac, pulmonary and renal diseases 4. Body Mass Index \> 30 kgm2. 5. Risk of aspiration. 6. Poor dentition with high risk of damage. 7. Patient refusal.

Design outcomes

Primary

Measure	Time frame
Optimal dose of alfentanil for successful LMA removal in spontaneously breathing anaesthetized adults	6 months

Secondary

Measure	Time frame
Number of patient with airway complication	after administration of alfentanil and within 1 min of LMA removal

Countries

Malaysia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026